Metric Finance
LearnFAQ
LearnFAQ

Learn / PBYI

NASDAQ: PBYI

Puma Biotechnology (PBYI) stock, explained like you're 5

Puma Biotechnology trades on the Nasdaq under the ticker PBYI. It is a small cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 531 million dollars.

Ticker
PBYI
Exchange
Nasdaq
Sector
Healthcare
Industry
Pharmaceutical Preparations
Size
Small cap, about 531 million dollars

Is Puma Biotechnology a small, medium or large cap company?

No. Puma Biotechnology is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 531 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Puma Biotechnology makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves PBYI stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Puma Biotechnology, Inc. (PBYI) Stock Price, News, Quote & History (Yahoo! Finance Canada)
  • Puma Biotechnology grants shares. TD Cowen targets Puma Biotechnology stock at USD 6.00 (ad-hoc-news.de)
  • A CEO's $16 per share warrant expired unexercised at Puma Biotechnology (PBYI). (Stock Titan)
  • Puma Biotechnology (PBYI) Stock Jumps On Profit Strength As Earnings Outlook Fades (Simply Wall Street)
  • Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why (TradingView)

Follow PBYI in your daily brief

Each trading day at 5 PM ET we post what happened to Puma Biotechnology and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow PBYI

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Puma Biotechnology stock

What does Puma Biotechnology do?

Puma Biotechnology trades on the Nasdaq under the ticker PBYI. It is a small cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 531 million dollars.

What is the ticker symbol for Puma Biotechnology?

Puma Biotechnology trades under the ticker PBYI on the Nasdaq.

What is Puma Biotechnology's market cap?

Puma Biotechnology is a small cap stock with a market cap of about 531 million dollars.

How does Puma Biotechnology make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves PBYI stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow PBYI stock every day?

Add PBYI to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow PBYI daily

A free brief on Puma Biotechnology and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • NVS · Novartis AG
  • AZN · Astrazeneca PLC
  • NVO · Novo Nordisk A S
  • VRTX · Vertex Pharmaceuticals Inc / Ma

Similar stocks

  • NVSNovartis AG
  • AZNAstrazeneca PLC
  • NVONovo Nordisk A S
  • VRTXVertex Pharmaceuticals Inc / Ma

Compare PBYI: PBYI vs NVS, PBYI vs AZN, PBYI vs NVO

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed